Drugs / INB301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07584057 | May 2026 → Feb 2030 expected | — | Yunnan Baiyao Group Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INB301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07584057 ↗ |
| Known as | INB301 Injection | “Each 1 mL of INB301 Injection contains 100 mg of the drug” NCT07584057 ↗ |
| Route | Subcutaneous | “receive subcutaneous injection of INB301” NCT07584057 ↗ |